SCHEMBL1374775

SCHEMBL1374775

CCOC(=O)CCCCCCC(=O)N1CCN(C(=O)c2ccc(N(C)C)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 3/20 0.46
GPR183 P32249 1/20 0.46
PLA2G2A P14555 2/20 0.45
KMT2A Q03164 2/20 0.44
CYP2C19 P33261 1/20 0.44
NAMPT P43490 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
CNR2 P34972 2/20 0.43
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1374136 0.85 BLM (0.59) RAB9AL3MBTL1GAANAMPTALDH1A1
SCHEMBL12431966 0.81 HDAC1 (0.45) GPR183PLA2G2ANAMPTCNR2
SCHEMBL12150973 0.81 HDAC1 (0.57)
SCHEMBL1374221 0.80 P2RY12 (0.57) RAB9AL3MBTL1GAAKMT2ANAMPT
SCHEMBL20197051 0.74 HPGD (0.53) L3MBTL1KMT2AALDH1A1MEN1MAPT
SCHEMBL1374666 0.73 MAPT (0.72) RAB9AL3MBTL1GAAKMT2ANAMPT
SCHEMBL31329295 0.72 L3MBTL1 (0.67) RAB9AL3MBTL1GAAKMT2ANAMPT
SCHEMBL1374750 0.71 ALDH1A1 (0.62) RAB9AL3MBTL1KMT2AALDH1A1MEN1
SCHEMBL5329789 0.71 L3MBTL1 (0.56) RAB9AL3MBTL1GAANAMPTALDH1A1
SCHEMBL1374125 0.71 HDAC1 (0.65) RAB9AL3MBTL1GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275810-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2011-11-10 US disclosed
US-7981895-B2 Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group TOPOTARGET UK LIMITED (GB) 2011-07-19 US disclosed
US-7629343-B2 Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-12-08 US disclosed
US-20080269237-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-10-30 US disclosed
EP-1492534-B1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LTD (GB) 2008-06-25 EP disclosed
US-20050143385-A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors TOPOTARGET UK LIMITED (GB) 2005-06-30 US disclosed
EP-1492534-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS TopoTarget UK Limited (GB) 2005-01-05 EP disclosed
WO-2003082288-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143385-A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors HDAC1, HDAC7, HDAC11 RAB9A 3354/4885L3MBTL1 1030/4885GAA 2192/4885
US-20080269237-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS HDAC5, HDAC1, HDAC7 RAB9A 3084/4885L3MBTL1 3908/4885GAA 796/4885
US-20110275810-A1 CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS HDAC5, HDAC1, HDAC7 RAB9A 3084/4885L3MBTL1 3908/4885GAA 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.